Navigation Links
Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Date:8/19/2007

boration with Novartis Pharma AG

-- Continuing the development of oral heparin; discussions with the US

Food and Drug Administration (FDA) has established a pathway for

registration to proceed into complete Phase III for the use of oral

heparin in the prevention of deep-vein thrombosis following elective

total hip replacement. Emisphere is in current discussions with

potential partners to complete the development of oral heparin in a

collaborative arrangement.

-- Continuing clinical development of oral insulin; an insulin/glucose

clamp study with a new formulation is being planned over a three-month

period starting early in the first quarter, which will provide further

data and information on the dosage. Collaborative partnerships will

then be investigated

Emisphere has five products in Phase I:

-- An Investigational New Drug application (IND) was filed by Genta

Incorporated on gallium nitrate on July 31, 2007

-- A program continues on an improved oral formulation of the antiviral

compound acyclovir with a pharmaceutical company outside of the United

States

-- A food-intake study for both GLP-1 and PYY will be undertaken later

this year at University Hospital, Switzerland

-- Parathyroid hormone continues on a progressive clinical development

path in collaboration with Novaris Pharma AG

Emisphere has 11 products in preclinical development:

-- Six projects with partners in obesity, osteoporosis, infectious

disease, diabetes, and CNS

-- Five projects without established collaborations for the therapies of

CNS, erectile dysfunction, cardiovascular disease, inflammation and

pain, and fertility treatment

-- Following completion of these pre-clinical projects, decisions would

then be taken to possibly proceed into future collaborations
'/>"/>

SOURCE Emisphere Technologies, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Texas , Nov. 26, 2014 ... today announced the completion of previously announced concurrent ... million.  After fees and estimated offering expenses, Lexicon ... the transactions.  The transactions consisted of: ... common stock, pursuant to a registration statement that ...
(Date:11/26/2014)... Calif. , Nov. 26, 2014  Avanir ... that the U.S. Food and Drug Administration (FDA) ... New Drug Application (NDA) for AVP-825. AVP-825 is ... sumatriptan powder delivered intranasally utilizing a novel Breath ... Complete Response letter, and consistent with the preliminary ...
(Date:11/26/2014)... 2014 Investor-Edge has initiated coverage on ... Horizon Pharma PLC (NASDAQ: HZNP ), Endocyte Inc. ... JNJ ), and Theravance Inc. (NASDAQ: THRX ... at: http://investor-edge.com/register . On Tuesday, November 25, ... Dow Jones Industrial Average edged 0.02% lower, to finish the ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
... Sept. 18 A long-term study found,that a ... with life-threatening,diseases, such as leukemia and lymphoma, results ... males are likely to recover,from these changes over ... In addition, neither male nor female long-term cancer,survivors ...
... Bacterial Infection and May ... Bacterial Infections, BOSTON, Sept. 18 Paratek ... of the Company,s,Multiple Adaptation Response (MAR) inhibitor program. ... controlling virulence and antibiotic,resistance. Paratek has shown that ...
Cached Medicine Technology:Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 2Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 3Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 4Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 3Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:11/28/2014)... Mabel’s Labels , the market ... an award-winning company established by four moms, today announced ... Tricia Mumby have been honored with a 2014 RBC ... PROFIT Award for Excellence in Entrepreneurship. , All 4 ... Mumby) accepted the award on behalf of Mabel’s Labels ...
(Date:11/28/2014)... Everett, WA (PRWEB) November 28, 2014 ... Snohomish County provides an overview of the influenza virus that ... annual flu season. , The article begins with a ... it manifests its symptoms. It reminds families that children under ... and those suffering from chronic diseases, such as heart and ...
(Date:11/28/2014)... FL (PRWEB) November 28, 2014 Lice Troopers ... areas of its in-home head lice service for moms ... in the center of Coral Gables on Pone De-leon Blvd ... Bay Harbor Islands that service Miami-Dade & Broward. Lice ... salon in South Florida which has been treating families for ...
(Date:11/28/2014)... Pittsburgh, PA (PRWEB) November 28, 2014 "Most ... have forced me to use crutches," said an inventor from ... better, more convenient way to support my foot, which inspired ... Foot Sling to offer a convenient way to support an ... to get around. It eliminates the need for crutches. The ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Schools ... value of providing quality commercial playground equipment to ... selected APCPLAY© to supply an affordable play structure ... City. , Centra provides comprehensive programs for ... and emotional support services. They have served ...
Breaking Medicine News(10 mins):Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2Health News:Lice Troopers Lice Removal Service Expands in Miami-Dade 2Health News:Centra Rivermont (VA) Provides School Playground Equipment from APCPLAY© for Special Needs Students 2Health News:Centra Rivermont (VA) Provides School Playground Equipment from APCPLAY© for Special Needs Students 3
... people newly diagnosed with HIV in the UK has ... with the transmission of antiretroviral-resistant HIV. // ... Protection Agency have investigated the connection between two phenomena: ... transmission, and the transmission of drug-resistant HIV. Sexually transmitted ...
... & Melinda Gates Foundation and the Medicines for Malaria ... center //in the United Arab Emirates (UAE). The center ... News reports. ,Gates Foundation and MMV representatives ... of Health to discuss the project. The foundation selected ...
... chances of contracting HIV by up to 60 percent, ... at increased risk of infection. // ,Early results ... potential impact of male circumcision on AIDS in Africa ... sex while healing from circumcision surgery, their female partners ...
... Dry Eye Syndrome (DES) has a significant impact on quality ... and 4.7% of men over 50, and affects over //4.8 ... have been identified, the cause of DES is still largely ... the quantity and/or quality of tears, an unstable tear film, ...
... and type 2 diabetes increases the risk of death for ... of heart disease deaths by itself, but together they’ve been ... an analysis of more than 900 patients with established coronary ... with both type 2 diabetes and symptoms of depression were ...
... of life are not sufficiently met and need to be upgraded ... systems do not reliably meet the needs of people living with ... and Joanne Lynn, two palliative care doctors based in the United ... we use language – and build health care systems – as ...
Cached Medicine News:Health News:STIs Significantly Increase Risk of Drug-resistant HIV Transmission 2Health News:Circumcision May Lift HIV Risk for Women 2Health News:Dry Eye Syndrome Affects Visual Functions 2Health News:Combination of Depression and Type-2-diabetes Lethal for Heart Patients 2Health News:Health Care Systems for Critically Ill Patients Need Restructuring 2
Serrated handle with polished finish. Non-magnetic. Straight tips: Delicate 11 mm. Most popular size or model....
Straight crisscross serrated tips. Flat handle with holes and polished finish....
1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish....
5 mm tying platform, serrated cross action handle with polished finish. Teeth: 0.10 mm, 1 x 2 set at 90 degrees....
Medicine Products: